With 3 approved biosimilars, at least 5 more awaiting approval, and launches expected to start as early as May 31, 2025, the Prolia / Xgeva (reference denosumab) $3.8 billion market is being closely watched.1 Five Biologics Price Competition and Innovation Act (BPCIA) litigations asserting a total of 47 patents have been filed to date, and